DIWALI SPECIAL

25% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim Offer →
logo

EVONILE vs SYMBIOTEC: Stock Comparison

EVONILE PHARMA vs SYMBIOTEC PHARMALABUpdated 6 Nov 26, 4:08 PM ISTNSE & company filings

SYMBIOTEC PHARMALAB is the larger company by market capitalisation. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

EVONILE leads 0; SYMBIOTEC leads 0 of 4

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

EVONILESYMBIOTEC

Valuation lens

What price are you paying?

Market CapContext only
₹4,233 Cr
₹9,799 Cr
P/E RatioSame reading
0x
—
P/B RatioSame reading
0x
—
EPSSame reading
—
₹2.24
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SYMBIOTEC is the larger company
₹9,799 Cr vs ₹4,233 Cr

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Price

MetricEVONILESYMBIOTEC
Live Price₹1,758.4₹1,513.6
Day Change2.44%19.04%
Volume52,65475.4 L
52-Week High₹1,738₹1,309.9
52-Week Low₹1,600.1₹934.2
Distance from 52W High1.17%15.55%

Valuation

MetricEVONILESYMBIOTEC
Market Cap₹4,233 Cr₹9,799 Cr
P/E Ratio0x—
P/B Ratio0x—
EPS—₹2.24
Dividend Yield0%0%

Growth

MetricEVONILESYMBIOTEC
Revenue Growth (TTM YoY)0%0%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth—0%
Qtr Profit Growth—0%

Profitability & Leverage

MetricEVONILESYMBIOTEC
Net Margin0%0%

Shareholding

As of Sep 2026 • change vs previous quarter
MetricEVONILESYMBIOTEC
Promoter Holding—33.28%
FII Holding—3.79%▼ 17.29 pp
DII Holding—33.17%▲ 5.65 pp
Public Holding—29.76%▲ 11.64 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: EVONILE PHARMA and SYMBIOTEC PHARMALAB.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.